---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-003645"
form_type: "8-K"
ticker: "GRCE"
cik: "0001444192"
company_name: "Grace Therapeutics, Inc."
filed_at: "2025-02-10T23:59:59+00:00"
generated_at: "2026-05-26T23:58:07.895344+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Grace Therapeutics: Phase 3 STRIVE-ON trial meets endpoint; announces up to $30M private placement

## Summary
- Phase 3 STRIVE-ON safety trial met primary endpoint: 19% reduction in clinically significant hypotension vs oral nimodipine; NDA submission expected H1 2025.
- Private placement of up to ~$30M gross proceeds ($15M upfront + up to $15M from warrant exercise); led by Nantahala Capital and ADAR1 Partners.
- Net proceeds ~$13.8M after fees; expected close Feb 11, 2025; funds for general corporate purposes and GTx-104 pre-commercial development.
- 54% of GTx-104 patients achieved ≥95% relative dose intensity vs 8% on oral nimodipine; favorable functional outcomes and fewer ICU days observed.
- Common warrants exercisable at $3.395/share; expire on earlier of 60 days post-FDA approval or Sep 25, 2028.

## SEC filing metadata
- accession: 0001140361-25-003645
- form_type: 8-K
- ticker: GRCE
- cik: 0001444192
- company_name: Grace Therapeutics, Inc.
- filed_at: 2025-02-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1444192/000114036125003645/0001140361-25-003645-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1444192/000114036125003645/ef20043150_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-003645
- JSON: https://secwatch.observer/filing/0001140361-25-003645.json
- Plain text: https://secwatch.observer/filing/0001140361-25-003645.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.